Glanbia (OTCMKTS:GLAPY) Lowered to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of Glanbia (OTCMKTS:GLAPY) from a hold rating to a sell rating in a research note issued to investors on Monday, Zacks.com reports.

According to Zacks, “Glanbia Plc engages in the manufacture and distribution of dairy and nutritional food products. Its operating segments include Glanbia Performance Nutrition, Global Ingredients, Dairy Ireland and Joint Ventures and Associates. Glanbia Performance Nutrition segment comprises of performance nutrition products under the Optimum Nutrition, BSN, Isopure, Nutramino and ABB brands. Global Ingredients segment includes American-style cheddar cheese, micro-nutrient premixes and dairy and non-dairy nutritional solutions. Dairy Ireland segment consists of consumer products and agribusiness. Joint Ventures and Associates segment covers Glanbia Ingredients Ireland, Glanbia Cheese and Southwest Cheese. Glanbia Plc is headquartered in Kilkenny, Ireland. “

Separately, Jefferies Financial Group raised shares of Glanbia from a hold rating to a buy rating in a research note on Friday, September 6th.

GLAPY opened at $59.01 on Monday. Glanbia has a fifty-two week low of $53.60 and a fifty-two week high of $107.19. The company’s 50 day moving average price is $60.77 and its two-hundred day moving average price is $69.45.

About Glanbia

Glanbia plc operates as a nutrition company worldwide. It operates through three segments: Glanbia Performance Nutrition, Glanbia Nutritionals, and Glanbia Ireland. The Glanbia Performance Nutrition segment manufactures and sells sports nutrition and lifestyle nutrition products in various formats, including powders, ready-to-eat bars and snacking foods, and ready-to-drink beverages through various channels, such as specialty retail, the Internet, and gyms, as well the food, drug, mass, and club channels.

Read More: What is a Candlestick Chart?

Get a free copy of the Zacks research report on Glanbia (GLAPY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Glanbia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glanbia and related companies with MarketBeat.com's FREE daily email newsletter.